Skip to menu
Oscotec Inc.
Translating science into medicine
Keep me signed in.
Find Account Info
Sign Up
Sign In
Sign Up
Sign In
HOME
COMPANY
About Us
History
Members
Contact Us
PIPELINE
Pipeline Overview
Rheumatoid arthritis
Immune thrombocytopenia
Acute myeloid leukemia
Non-small cell lung cancer
Alzheimer's disease
NEWSROOM
Notice
Press Releases
Publications
IR Materials
Shareholder Notice
PRESS
주주님들께 드리는 글
2022.08.30
SCI Journal - SKI-G-8...
2022.02.16
FLT3/AXL Inhibitor (A...
2020.06.22
HOME
COMPANY
About Us
History
Members
Contact Us
PIPELINE
Pipeline Overview
Rheumatoid arthritis
Immune thrombocytopenia
Acute myeloid leukemia
Non-small cell lung cancer
Alzheimer's disease
NEWSROOM
Notice
Press Releases
Publications
IR Materials
Shareholder Notice
×
WELCOME
Keep me signed in.
Find Account Info
×
LANGUAGE : English
한국어
NEWSROOM
Notice
Press Releases
Publications
IR Materials
Notice
Press Releases
Publications
IR Materials
NEWSROOM
- Notice
- Press Releases
- Publications
- IR Materials
Home
NEWSROOM
Press Releases
T
Default
Default
✔
나눔고딕
✔
Segoe UI
✔
Tahoma
✔
✔
Go Website with Viewer
Search
Write
Subject+Content
Subject
Content
Comment
User Name
Nick Name
User ID
Tag
Search
List
Zine
Gallery
List of Articles
Date
Website
Media
Pipeline
2021-03-02
Other news to note for March 2, 2021
BioWorld
Oscotec
2021-03-02
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
CISION
Oscotec
2020-05-18
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
BioSpace
Lazertinib
2019-12-14
Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC
Targeted Oncology
Lazertinib
2019-12-12
Yuhan to start phase-3 trial on lung cancer drug Lazertinib
KBR (; Korea Biomedical Review)
Lazertinib
2019-12-02
"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"
PRNewswire
Genosco
2019-11-04
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Molecular Cancer
SKI-G-801
2019-11-04
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
THE LANCET ONCOLOGY
Lazertinib
2019-07-01
Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models
CANCER RESEARCH
SKI-G-801
2019-06-25
Oscotec wins exception policy for continued R&D for new drugs
KBR (; Korea Biomedical Review)
Oscotec
2019-01-28
Genosco gears up for IPO
THE INVESTOR
Genosco
2018-11-23
Oscotec`s acute leukemia treatment wins orphan drug status from FDA
KBR (; Korea Biomedical Review)
SKI-G-801
Board Pagination
Prev
1
2
Next
/ 2
GO
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.